Payment overview · 2025
General Payments
$482.84
25 reported records · 10 companies
Healthcare provider profile · identity verified
Eric Hart, PHYSICIAN ASSISTANT
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · SAVANNAH, TN · NPI 1790168938
Verified facts
What the public records show
CMS Open Payments records show Eric Hart, PHYSICIAN ASSISTANT received $482.84 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $197.58 | 40.9% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.35 | 12.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.65 | 9.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.59 | 9.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.58 | 8.2% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $24.48 | 5.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.18 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.84 | 3.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.00 | 3.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.59 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $482.84 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $90.85 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $84.14 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.35 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.35 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.59 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.59 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 171 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 94 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
80 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
154 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
171 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 386 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 376 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 373 | 102 |
| Omeprazole | Omeprazole | 358 | 84 |
| Losartan Potassium | Losartan Potassium | 313 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 300 | 70 |
| Lisinopril | Lisinopril | 291 | 78 |
| Furosemide | Furosemide | 261 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 66 |
| Tramadol Hcl | Tramadol Hcl | 223 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 194 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 51 |
| Metformin Hcl | Metformin Hcl | 177 | 44 |
| Potassium Chloride | Potassium Chloride | 177 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 176 | 46 |
| Ozempic | Semaglutide | 171 | 28 |
| Farxiga | Dapagliflozin Propanediol | 154 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 40 |
| Jardiance | Empagliflozin | 152 | 28 |
| Trazodone Hcl | Trazodone Hcl | 143 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 130 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 30 |
| Alprazolam | Alprazolam | 124 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 37 |
| Glipizide | Glipizide | 110 | 30 |
| Sertraline Hcl | Sertraline Hcl | 107 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 28 |
| Eliquis | Apixaban | 97 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 19 |
| Rybelsus | Semaglutide | 94 | 19 |
| Clonazepam | Clonazepam | 93 | 14 |
| Carvedilol | Carvedilol | 92 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 67 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 89 | 18 |
| Buspirone Hcl | Buspirone Hcl | 88 | 14 |
| Levetiracetam | Levetiracetam | 87 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 32 |
| Xarelto | Rivaroxaban | 85 | 15 |
| Linzess | Linaclotide | 80 | 22 |
| Meloxicam | Meloxicam | 77 | 24 |
| Simvastatin | Simvastatin | 77 | 21 |
| Famotidine | Famotidine | 74 | 21 |
| Alendronate Sodium | Alendronate Sodium | 71 | suppressed |
| Mirtazapine | Mirtazapine | 71 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 68 | 21 |
| Celecoxib | Celecoxib | 67 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 29 |
| Allopurinol | Allopurinol | 63 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 15 |
| Donepezil Hcl | Donepezil Hcl | 59 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 12 |
| Meclizine Hcl | Meclizine Hcl | 57 | 14 |
| Memantine Hcl | Memantine Hcl | 56 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 33 |
| Bydureon Bcise | Exenatide Microspheres | 52 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 52 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 45 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 15 |
| Lovastatin | Lovastatin | 45 | 13 |
| Prednisone | Prednisone | 44 | 31 |
| Pregabalin | Pregabalin | 44 | suppressed |
| Calcitriol | Calcitriol | 43 | suppressed |
| Lorazepam | Lorazepam | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Nystatin | Nystatin | 41 | 19 |
| Cefdinir | Cefdinir | 40 | 37 |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Diazepam | Diazepam | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 28 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 26 |
| Rexulti | Brexpiprazole | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Colchicine | Colchicine | 21 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 17 |
| Topiramate | Topiramate | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 13 |
| Gemtesa | Vibegron | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $482.84 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, FREESTYLE LIBRE 3, IBSRELA, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error